Fig. 4
From: Teriparatide treatment in severe osteoporosis – a controlled 10-year follow-up study
Health Related Quality of Life (HRQoL) for patients treated with teriparatide and for the population sample. EQ5D-VAS (median score between 0 and 100 mm). Comparison between the WHO MONICA population at start and teriparatide at treatment start (p < 0.001); between teriparatide treatment start and treatment cessation after 1.5 years (p = 0.78) and between teriparatide at start and after 10 years for the patients with osteoporosis, respectively (p = 0.69)